Prestige BioPharma Limited (KRX:950210)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,030
-180 (-1.47%)
At close: Jan 16, 2026
-20.07%
Market Cap144.59B
Revenue (ttm)14.41B
Net Income (ttm)15.76B
Shares Out12.02M
EPS (ttm)262.37
PE Ratio45.85
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume133,655
Average Volume142,062
Open12,210
Previous Close12,210
Day's Range11,910 - 12,210
52-Week Range11,000 - 20,000
Beta0.97
RSI39.12
Earnings DateFeb 27, 2026

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines in Singapore. The company’s approved product is Trastuzumab Biosimilar for treatment the of early breast cancer, metastatic breast cancer, and metastatic gastric cancer. In addition, its pipeline includes Adalimumab, which is in phase 1 trial for arthritis; and Bevacizumab, in phase 3 clinical study for non-small cell lung cancer, colorectal cancer. It is also developing diagn... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Singapore
Stock Exchange Korea Stock Exchange
Ticker Symbol 950210
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.